StockData
Solid Biosciences Inc. logo

Solid Biosciences Inc. (SLDB) stock

SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$6.35+0.12 (+1.93%)

Close on Nov 18, 2026Market cap $680.88MP/E –Yield –

Solid Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Solid Biosciences's revenue for the twelve months ending Dec 31, 2020 was $0. For fiscal 2022 it was $8.09M, down 40.6% from the year before. The highest annual figure on record is $13.62M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$8.09M-40.6%
FY2021Dec 31, 2021$13.62M–
FY2020Dec 31, 2020$0–
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$0–

More Solid Biosciences figures

See a number that looks wrong?